title: The role of naftopidil in the management of benign prostatic hyperplasia.
abstract: Naftopidil, which to a certain extent shows an affinity to α1D-adrenoceptor subtype in addition to a high affinity to α1A-adrenoceptor, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS). The aim of the present review is to systematically refer to the published studies on this unique agent for BPH. Based on a randomized prazosin-controlled study and another double-blind placebo-controlled study, which verified the dose-dependent effects of naftopidil, the Japanese Ministry of Health, Labor and Welfare approved naftopidil for treating men with BPH in 1996. Several tamsulosin-controlled studies have suggested treatment effects of naftopidil similar to those of tamsulosin and potentially higher efficacy for alleviating storage symptoms by naftopidil. Although well-designed, randomized studies are warranted to confirm the long-term outcomes and effector/target of naftopidil, the α1A-antagonist naftopidil, which also blocks α1D-adrenoceptor, improves voiding symptoms, and may also be useful for the management of men with storage symptoms represented by nocturia, retrieving their quality of life impaired by BPH-associated LUTS.
authors.affiliation: Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, Japan.
authors.forename: Noboru
authors.initials: N
authors.lastname: Hara
authors.forename: Takaki
authors.initials: T
authors.lastname: Mizusawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Obara
authors.forename: Kota
authors.initials: K
authors.lastname: Takahashi
keywords: benign prostatic hyperplasia; lower urinary tract symptoms; α1-adrenoceptor subtypes
references.citation: Jpn J Pharmacol. 1999 Apr;79(4):447-54
references.pmid: 10361884
references.citation: Urology. 1998 Mar;51(3):428-36
references.pmid: 9510348
references.citation: Prostate. 2009 Oct 1;69(14):1521-8
references.pmid: 19544328
references.citation: J Urol. 1999 Feb;161(2):635-40
references.pmid: 9915474
references.citation: Int J Urol. 2006 Jul;13(7):932-8
references.pmid: 16882058
references.citation: Hinyokika Kiyo. 2002 Jan;48(1):7-11
references.pmid: 11868386
references.citation: J Cataract Refract Surg. 2005 Apr;31(4):664-73
references.pmid: 15899440
references.citation: Int J Urol. 2003 Nov;10(11):587-94
references.pmid: 14633083
references.citation: J Urol. 1998 Sep;160(3 Pt 1):937-43
references.pmid: 9720591
references.citation: Prostate. 1994 Jul;25(1):46-52
references.pmid: 7517541
references.citation: Int J Urol. 2006 Jan;13(1):15-20
references.pmid: 16448426
references.citation: Urology. 2008 Nov;72(5):1051-5
references.pmid: 18817955
references.citation: Jpn J Pharmacol. 1991 Mar;55(3):391-8
references.pmid: 1677438
references.citation: Hinyokika Kiyo. 2004 May;50(5):309-14
references.pmid: 15237482
references.citation: Am J Ophthalmol. 2007 Jan;143(1):150-1
references.pmid: 17188051
references.citation: Hinyokika Kiyo. 1991 Dec;37(12):1759-72
references.pmid: 1723843
references.citation: Asian J Androl. 2007 Nov;9(6):771-80
references.pmid: 17968462
references.citation: BJU Int. 2003 Sep;92(4):409-14
references.pmid: 12930430
references.citation: Am J Manag Care. 2002 Dec;8(19 Suppl):S616-30
references.pmid: 12516956
references.citation: BJU Int. 2011 Jul;108(1):100-7
references.pmid: 21062392
references.citation: Urol Int. 2009;83(1):49-54
references.pmid: 19641359
references.citation: Value Health. 2009 Jun;12(4):568-73
references.pmid: 18783391
references.citation: Int J Urol. 2010 Jun;17(6):555-62
references.pmid: 20370847
references.citation: J Urol. 2005 Jul;174(1):370-4
references.pmid: 15947692
references.citation: Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
references.pmid: 17049716
references.citation: Int J Urol. 2008 Aug;15(8):709-15
references.pmid: 18662175
references.citation: Arzneimittelforschung. 1991 Sep;41(9):924-31
references.pmid: 1796920
references.citation: Int J Urol. 2009 Mar;16(3):299-302
references.pmid: 19207610
references.citation: BJU Int. 2005 Sep;96(4):581-6
references.pmid: 16104914
references.citation: Prostate Suppl. 1989;2:69-77
references.pmid: 2482774
references.citation: BMJ. 1994 Apr 9;308(6934):929-30
references.pmid: 8173393
references.citation: Urol Int. 2009;82(2):136-42
references.pmid: 19321997
references.citation: Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e385-92
references.pmid: 21664068
references.citation: Scand J Urol Nephrol. 2010 Feb;44(1):38-45
references.pmid: 20095868
references.citation: World J Urol. 2011 Apr;29(2):225-31
references.pmid: 20309563
references.citation: Adv Urol. 2011;2011:804583
references.pmid: 21603217